GLPG Oct 2024 30.000 call
| Previous close | 2.1500 |
| Open | 2.1000 |
| Bid | 1.1000 |
| Ask | 5.0000 |
| Strike | 30.00 |
| Expiry date | 2024-10-18 |
| Day's range | 2.1000 - 2.1500 |
| Contract range | N/A |
| Volume | |
| Open interest | 20 |
GlobeNewswireGalapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024
Mechelen, Belgium; June 14, 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present encouraging new data from the ongoing Phase 1/2 ATALANTA-1 study of CD19 CAR-T candidate, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma (R/R NHL) at the annual European Hematology Association (EHA) 2024 Hybrid Congress. Galapagos' product candidate GLPG5101 is produced using the company's innovative, decentralized T-cell manufacturing platform. The oral presentation in
Simply Wall St.Retail investors are Galapagos NV's (AMS:GLPG) biggest owners and were hit after market cap dropped €74m
Key Insights Significant control over Galapagos by retail investors implies that the general public has more power to...
- GlobeNewswire
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next generation MAGE-A4 TCR T-cell therapy) produced on Galapagos’ decentralized manufacturing platform in patients with head & neck cancerUza-cel has shown encouraging results in head & neck cancer with partial responses in four out of five patients to date in a Phase 1 trial using Adaptimmune’s centralized manufacturing platform Initial in vitro testing of uza-cel produced on Ga
